Fate Therapeutics to Present at the 5th Annual Cell & Gene Therapy Investor Day
April 20 2017 - 8:00AM
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, today announced that Scott Wolchko, President and Chief
Executive Officer, will present at the 5th Annual Cell & Gene
Therapy Investor Day in Boston on Thursday, April 27, 2017 at 9:25
a.m. ET.
A live webcast of the presentation will be
available through the investor relations section of the Company's
website at www.fatetherapeutics.com. Following the live webcast, an
archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.Fate
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for cancer and immune disorders. The Company's hematopoietic cell
therapy pipeline is comprised of NK- and T-cell immuno-oncology
programs, including off-the-shelf product candidates derived from
engineered induced pluripotent cells, and immuno-regulatory
programs, including product candidates to prevent life-threatening
complications in patients undergoing hematopoietic cell
transplantation and to promote immune tolerance in patients with
autoimmune disease. Its adoptive cell therapy programs are based on
the Company's novel ex vivo cell programming approach,
which it applies to modulate the therapeutic function and direct
the fate of immune cells. Fate Therapeutics is headquartered in San
Diego, CA. For more information, please
visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Sep 2023 to Sep 2024